26159-34-2Relevant articles and documents
A Ru(II)-p-cymene compound bearing naproxen-pyridineamide. Synthesis, spectroscopic studies, computational analysis and in vitro anticancer activity against lung cells compared to Ru(II)-p-cymene-naproxen and the corresponding drug ligands
Tabares, Julie Pauline Gaitan,Santos, Rodrigo Luis S.R.,Cassiano, Jefferson Luiz,Zaim, Marcio H.,Honorato, Jo?o,Batista, Alzir A.,Teixeira, Sarah F.,Ferreira, Adilson Kleber,Viana, Rommel B.,Martínez, Sandra Quispe,Stábile, Antonio Carlos,de Oliveira Silva, Denise
, p. 27 - 38 (2019)
The design of new Ru(II) organometallics is a subject of interest to the field of anticancer metallodrugs. This work reports the interaction of the Ru(II)-η6-p-cymene framework with naproxen-pyridineamide (Npxpya, L1), a structurally modified form of the naproxen (HNpx, HL2) drug, to give the new organometallic [Ru(η6-p-cymene)(L1)Cl2] (1) bearing the Npxpya ligand. The reported naproxenate-derived, [Ru(η6-p-cymene)(L2)Cl] (2), is re-prepared, also from the precursor [Ru(η6-p-cymene)Cl2]2 (3), and additional investigation is performed. The two Ru(II)-arenes and the L1 ligand are fully characterized by ESI-MS, NMR, ATR/FT-IR and UV/VIS, and their structures corroborated by DFT computational calculations. Time-dependent 1H MNR studies show that both Ru(II)-arenes, despite being stable in non-coordinating solvents, undergo distinct step dissociation in dimethylsulfoxide solvent to give the corresponding drug ligands and [Ru(η6-p-cymene)(dmso)Cl2] (4) species. Electronic absorption spectroscopy experimental data show good correlation with DFT calculations. Organometallics 1 and 2, as well as their corresponding parent drug ligands, exhibit luminescence properties mainly associated to the naproxen moiety. Screening in NCI-H460 and A549 lung cancer cells reveals lack of activity for 2 and L2, while the new organometallic 1 is found to inhibit cell proliferation of both types of cell lines in similar way to the L1 drug. The structural modification, by inserting the pyridineamide moiety into the original structure of naproxen to form the Npxpya conjugated drug, is shown to be crucial for the anticancer activity. Compound 1, despite having IC50 close to the IC50 of L1, does not show significant effect on the mitochondrial membrane potential (MMP), in contrast to the behavior of the free L1 parent drug which significantly decreases the MMP in NCI-H460 cells. Interestingly, since 1H MNR studies indicate that organometallic 1 is completely dissociated in dmso (the solvent used to prepare the drug solutions for cell treatment in the biological assays) to give the L1 free drug and species 4, it is plausible to infer that the presence of Npxpya-free Ru species, probably in the form of species 4, might play a role in inhibiting the mechanism related to the mitochondrial function when the cells are treated with 1, in comparison with the cell treatment with the L1 free drug.
Growth, shrinking, and breaking of pluronic micelles in the presence of drugs and/or β-cyclodextrin, a study by small-angle neutron scattering and fluorescence spectroscopy
Valero, Margarita,Dreiss, Cecile A.
experimental part, p. 10561 - 10571 (2011/01/12)
The associative structures between F127 Pluronic micelles and four drugs, namely, lidocaine (LD), pentobarbital sodium salt (PB), sodium naproxen (NP), and sodium salicylate (SAL), were studied by small-angle neutron scattering (SANS). Different outcomes for the micellar aggregates are observed, which are dependent on the chemical nature of the drug and the presence of charge or otherwise: the micelles grow with LD, are hardly modified with PB, and decrease in size with both NP and SAL. The partition coefficient, determined by fluorescence spectroscopy, is directly correlated to the amount of charge, following NP ≈ SAL a slightly deeper localization of LD and more superficial for PB. All drugs can form inclusion complexes with heptakis(2,6-di-O-methyl) β-cyclodextrin (hep2,6 β-CD). Hep2,6 β-CD, as shown in previous studies (Joseph, J.; Dreiss, C. A.; Cosgrove, T. Langmuir, 2008, 24, 10005-10010; Dreiss, C. A.; Nwabunwanne, E.; Liu, R.; Brooks, N. J. Soft Matter, 2009, 5, 1888-1896), is also able to form a complex with F127, resulting in micellar breakup. In the ternary mixtures, a fine balance of forces is involved, which results in drastic micellar changes, as observed from the SANS patterns. Depending on the ratio of drug, polymer, and hep2,6 β-CD and the nature of the interactions (which is directly linked to the drug chemical structure), the presence of drug either hinders micellar breakup by β-CD (at high enough concentration of LD or PB) or leads to micellar growth (NP). These effects are mainly attributed to a preferential drug/β-CD interaction (except for PB), which, at least in the conditions studied here, explains the higher β-CD concentration needed for micellar breakup to occur.
NAPROXCINOD PROCESS AND SOLID DISPERSION
-
Page/Page column 28, (2009/12/28)
Processes for the preparation of naproxcinod and its purification, solid dispersions of naproxcinod with a pharmaceutically acceptable carrier, and processes for making dispersions. Also provided is crystalline 2-(S)-(4-chlorobutyl)-2-(6-methoxy-2-naphthyl)-propanoate and methods for its preparation.
Process for chiral enrichment of optically active carboxylic acids or salts or esters thereof
-
, (2008/06/13)
A highly efficient method for enriching the chiral purity of a partially enriched mixture of enantiomers of an optically active compound, a major portion of the partially enriched mixture of enantiomers comprising a first enantiomer of the optically active compound, a minor portion of the partially enriched mixture of enantiomers comprising a second enantiomer of the optically active compound. The method comprises mixing an acid in whatever form it may exist in solution with an aqueous solution of the partially enriched mixture of enantiomers, in whatever form the partially enriched mixture of enantiomers may exist in solution, to form a reaction mass comprising a further enriched mixture of enantiomers of the optically active compound, the further enriched mixture of enantiomers having a higher percentage of the first enantiomer than the partially enriched mixture. The optically active compound has the formula: where R1, R2, and R3 are different from each other and are selected from the group consisting of a hydrogen atom, hydrocarbyl groups, hydrocarbyloxy groups, hydrocarbylthio groups, hydrocarbylcarbonyl groups, halohydrocarbyl groups, hydrocarbyloxyhydrocarbyl groups, heteroaromatic groups, and halogen atoms, with the proviso that none or only one of R1, R2, and R3 can be a halogen atom, and where Z is an alkali metal cation, a cation of a nitrogenous base or a combination of the foregoing.
Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate
-
, (2008/06/13)
Novel and very useful forms of sodium (S)-2-(6-methoxy-2-naphthyl)propionate are provided. These forms are sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate having an average particle size significantly larger than about 70 microns--the size of conventional sodium (S)-2-(6-methoxy-2-naphthyl)propionate--and a chiral purity of at least 98% (S)-enantiomer. Process technology enabling the production of such novel products is also described. The provision of such novel products makes possible significant improvements in processing time, plant capacity and product handling operations.
Manufacture of optically active α-arylalkanoic acids and precursors thereof
-
, (2008/06/13)
This invention concerns a new process of preparing optically active α-arylalkanoic acids and their precursors. These α-arylalkanoic acids, esters, amides, nitriles, oxazolines and metal salts are stereoselectively prepared by forming the metal or metal halide of the corresponding acid, ester, amide, oxazoline, nitrile, or metal salt and treating the compound so prepared with an aryl halide in the presence of a chiral (optically active) transition metal catalyst of the formula (LL*)QZT wherein Q is a transition metal selected from palladium and nickel; Z and T are independently halogen; and LL* is a chiral tertiary diphosphine compound capable of acting as a bidentate ligand with Q to form a 5-membered ring, optionally in the presence of a dipolar aprotic solvent or mixtures thereof, for a time sufficient to form the corresponding optically active α-arylalkanoic acid, ester, amide, nitrile, oxazoline or metal salt, and optionally concomitantly or sequentially hydrolyzing any ester, amide, nitrile, oxazoline or metal salt formed to the corresponding optically active α-arylalkanoic acid. The process optionally further includes removal of halogen atom from the aromatic portion of the α-arylalkanoic acid. The process optionally includes subsequent formation of the pharmaceutically acceptable salts and esters of the optionally active α-arylalkanoic acid. This is a simple process for the preparation of the described optically active α-arylalkanoic acids. These compounds are useful as pharmaceutical (e.g., anti-inflammatory) agents.
Optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl) amino-1-propanone, its derivatives and their halo analogs and the methods for their manufacture
-
, (2008/06/13)
A manufacturing method is described for the preparation of optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl)amino-1-propanone, its derivatives and their halo analogs. The optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl)amino-1-propanone, its derivatives and their halo analogs are useful intermediates in the preparation of 2-(6-methoxy-2-naphthyl)propionic acid, which is useful as pharmaceutical, e.g. antiinflammatory, analgesic and anti-pyretic agents.
